本文選題：難治性功能性便秘 + 老年　； 參考：《重慶醫(yī)學(xué)》2017年20期

【摘要】：目的比較普蘆卡必利、莫沙必利分別聯(lián)用小劑量聚乙二醇治療老年難治性功能性便秘的短期療效。方法對(duì)2014年5月至2016年2月在該院門診診治的老年難治性功能性便秘患者90例進(jìn)行回顧性分析。入選病例分為兩組,每組45例。普蘆卡必利組:琥珀酸普蘆卡必利片,2mg,每日1次;莫沙必利組:枸櫞酸莫沙必利膠囊,5mg,每日3次。兩組均聯(lián)用復(fù)方聚乙二醇電解質(zhì)散(PEG)13.125g,每日2次,療程4周。觀察兩組患者首次排便和排便困難緩解時(shí)間、每周完全自發(fā)排便(SCBM)平均次數(shù)、排便困難、大便性狀、不良反應(yīng)及生命質(zhì)量的變化。結(jié)果兩組慢傳輸型、排便障礙型的治療有效率比較,差異均有統(tǒng)計(jì)學(xué)意義(P0.05),混合型差異無統(tǒng)計(jì)學(xué)意義(P0.05)。與莫沙必利組比較,普盧卡必利組首次排便時(shí)間和排便困難緩解時(shí)間均較短,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后4周,兩組患者SCBM3次,普盧卡必利組次數(shù)更多;普蘆卡必利組排便困難改善更為明顯,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。大便性狀改善組間比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義(P0.05),不良反應(yīng)發(fā)生率比較差異無統(tǒng)計(jì)學(xué)意義(P0.05)。治療后4周,兩組患者便秘患者生存質(zhì)量自評(píng)量表(PAC-QOL)評(píng)分的總均分均有下降,普蘆卡必利組降低更為明顯,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論普蘆卡必利+PEG治療老年難治性功能性便秘起效更快,且在總體療效及生命質(zhì)量改善方面有優(yōu)勢(shì),尤適用于慢傳輸型和排便障礙型。
[Abstract]:Objective to compare the short-term efficacy of prucapride and mosapride in the treatment of refractory functional constipation in the elderly. Methods from May 2014 to February 2016, 90 elderly patients with refractory functional constipation were analyzed retrospectively. The patients were divided into two groups, 45 cases in each group. Prucapride group: 2 mg of prucapride succinate tablets, once a day; mosapride group: 5 mg of mosapride citrate capsule, 3 times a day. Both groups were treated with compound polyethylene glycol electrolyte powder (PEG) 13.125 g twice a day for 4 weeks. The first defecation and defecation difficulty relief time, the average times of complete spontaneous defecation per week, defecation difficulty, defecation character, adverse reaction and quality of life were observed in the two groups. Results the effective rates of slow transmission and defecation disorder in the two groups were significantly higher than those in the control group (P 0.05), but there was no significant difference between the mixed type and the control group (P 0.05). Compared with mosapride group, the first defecation time and defecation difficulty relief time were shorter in Pulucapride group, and the difference was statistically significant (P 0.05). Four weeks after treatment, SCBM3 times in the two groups, Prucapride group more times, the improvement of defecation difficulty was more obvious in the prucapride group, the difference was statistically significant (P 0.05). There was no significant difference between the two groups in improving defecation traits (P 0.05). There was significant difference in the total effective rate between the two groups (P 0.05), but there was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). At 4 weeks after treatment, the total mean score of PAC-QOLscore of patients with constipation in both groups was decreased, especially in the prucapride group, and the difference was statistically significant (P 0.05). Conclusion prucapride PEG is more effective in the treatment of refractory functional constipation in the elderly, and has advantages in improving the overall curative effect and quality of life, especially for slow transit type and defecation disorder type.
【作者單位】： 廣東省河源市源城區(qū)人民醫(yī)院消化內(nèi)科;
【分類號(hào)】：R574.62

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李玉璽;;莫沙必利治療老年人慢性功能性便秘療效觀察[J];工企醫(yī)刊;2006年06期

2 王清奎;;復(fù)方蘆薈膠囊與莫沙必利治療老年性便秘的體會(huì)[J];中國(guó)社區(qū)醫(yī)師(綜合版);2007年16期

3 季潔如;高瑋;許平;王天蓉;陳勝良;;莫沙必利治療餐后不適綜合征和上腹痛綜合征隨機(jī)、雙盲、安慰劑對(duì)照研究[J];胃腸病學(xué);2008年11期

4 韋揚(yáng);鄒世昌;;莫沙必利聯(lián)合六味地黃丸治療便秘型腸易激綜合征[J];中國(guó)民間療法;2010年02期

5 曾雯君;汪琳;施義方;;莫沙必利聯(lián)合中藥治療便秘型腸易激綜合征的臨床療效觀察[J];中國(guó)初級(jí)衛(wèi)生保健;2012年01期

6 高欣;張振玉;;莫沙必利在胃腸道以外疾病中的應(yīng)用[J];醫(yī)學(xué)綜述;2012年17期

7 羅斌;梁碧濤;;雙歧桿菌聯(lián)合莫沙必利治療老年慢性功能性便秘34例[J];中國(guó)老年學(xué)雜志;2012年24期

8 陸元漢;;莫沙必利聯(lián)合福松治療便秘型腸易激綜合征臨床觀察[J];中國(guó)醫(yī)藥指南;2008年13期

9 林金坤;任明;彭曉忠;肖英蓮;王思云;楊莉;陳e，

本文編號(hào)：1994472